The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for chronic lung disease bronchiectasis in the US. The regulator has set a ...

A subtle sign of lung cancer can be detected by doing a quick 'finger test' at home. Fingernails, if they change colour or shape, can sometimes indicate potential health issues. When it comes to lung ...

The new NHS online hospital service being launched in England next year will initially focus on menopause, prostate and eye conditions. The NHS has selected nine different conditions in total for the ...

It started out as a typical hot yoga class for Lavonda. The North Carolina resident was used to strenuous workouts, but on this day in 2008 she felt faint as she went through the sequence of poses.

The European Medicines Agency (EMA) has recommended granting marketing authorization in the EU for brensocatib (Brinsupri, Insmed Incorporated) for non-cystic fibrosis bronchiectasis (NCFB) in ...

Queen's University Belfast-led research reports on a multicenter trial finding no significant reduction in pulmonary exacerbations with hypertonic saline or carbocisteine over 52 weeks among adults ...

Bronchiectasis is a long-term lung condition where the airways stay widened and inflamed. These airway changes make it harder to breathe and clear mucus. People with bronchiectasis live with a ...

MPR: What is non-cystic fibrosis bronchiectasis? Dr Addrizzo-Harris: Non-cystic fibrosis bronchiectasis is an abnormality of the airways in the lung where the airways become dilated, often permanently ...

Treatment with brensocatib 10 mg and 25 mg significantly reduced the annual rate of pulmonary exacerbations in patients with NCFB. The Food and Drug Administration (FDA) has approved Brinsupri ™ ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name ...

WEDNESDAY, Aug. 13, 2025 (HealthDay News) — For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has approved Insmed’s daily pill ...

Brinsupri (brensocatib) is a new oral medicine approved to treat a long-term lung disease known as non-cystic fibrosis bronchiectasis (NCFB) in adults and children ages 12 or older. It works by ...